Bolt Biotherapeutics
BOLT
25 hedge funds and large institutions have $5.1M invested in Bolt Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 6 closing their positions.
43.91% more ownership
Funds ownership: 2.39% → 46.3% (+44%)
14% less funds holding
Funds holding: 29 → 25 (-4)
30% less capital invested
Capital invested by funds: $7.33M → $5.1M (-$2.23M)
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$54.2K |
| 2 |
Morgan Stanley
New York
|
+$19.8K |
| 3 |
Renaissance Technologies
New York
|
+$17.3K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$3.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$157K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$35.7K |
| 3 |
BlackRock
New York
|
-$19.1K |
| 4 |
State Street
Boston,
Massachusetts
|
-$19K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$16.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
State Street
Boston,
Massachusetts
| – | -$19K | -2,372 | Closed |
|
|
27
Northern Trust
Chicago,
Illinois
| – | -$16.4K | -2,045 | Closed |
|
28
Mariner
Overland Park,
Kansas
| – | -$16K | -2,000 | Closed |
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$8.69K | -1,087 | Closed |
|
|
SG
30
StoneX Group
New York
| – | -$6.21K | -777 | Closed |
|
|
XT
31
XTX Topco
George Town,
Cayman Islands
| – | -$6.16K | -770 | Closed |
|
BOLT Hedge Fund Activity: Q2 2025 in Review
25 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2025, worth a combined $5.1M — down 30% from $7.33M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BOLT and 2 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 5 added.
The largest buyer was Squarepoint, adding an estimated $54.2K. The largest seller was Tang Capital Management, cutting an estimated $157K.
- 25 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2025, down from 29 in Q1 2025.
- Funds reported $5.1M of Bolt Biotherapeutics stock for Q2 2025, down 30% quarter-over-quarter.
- 2 funds opened new Bolt Biotherapeutics positions in Q2 2025 and 6 closed out, a net change of -4 holders.
- The largest Bolt Biotherapeutics buyer in Q2 2025 was Squarepoint, an estimated $54.2K added.
- The largest Bolt Biotherapeutics seller in Q2 2025 was Tang Capital Management, an estimated $157K sold.
Based on aggregated 13F filings for Q2 2025.